<DOC>
	<DOCNO>NCT02153762</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability , well effectiveness , regard order application Locoid Lipocream Hylatopic Plus cream patient atopic dermatitis ( AD ) , type skin rash.Topical skin barrier repair therapy ( BRT ) plain moisturize creams/lotions add lipid ( fats/oils ) , Hylatopic Plus cream , emerge effective addition treatment atopic dermatitis . BRTs often use along topical steroid ( medicate cream ) , Locoid lotion , skin AD , monotherapy ( single treatment ) non-diseased diseased skin . Since BRTs help restore component skin absent skin AD , believe long-term BRT use may reduce development AD . This open-label , single site study .</brief_summary>
	<brief_title>Treatment Atopic Dermatitis With Different Orders Application Locoid Lotion Hylatopic Plus Cream</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Hydrocortisone-17-butyrate</mesh_term>
	<criteria>subject least 3 month age . clinical diagnosis stable mild moderate AD use Hanifin Rajka criterion diagnose AD AD lesion similar size severity bilateral anatomic location SPGA score 2 3 least 10 % BSA involvement baseline good health , without evidence disease process ( e ) would present patient safety concern confound factor assessment study objective able willing understand sign inform consent ( applicable parent legal guardian sign inform consent ) , able willing agree requirement restriction study Subjects willing discontinue systemic corticosteroid , immunomodulators , ultra violet light therapy medication ( investigational otherwise ) may effect atopic dermatitis disease progression 30 day prior baseline measurement . Subjects stable maintenance therapy ( least 30 day use prior baseline ) antihistamines and/or nasal spray contain corticosteroid treatment bronchial asthma allergic rhinitis , antibiotic treatment acne allow . Subjects willing discontinue use topical treatment AD include , limited , corticosteroid , immunomodulators , vitamin D treatment , retinoids , topical antihistamine least 14 day prior baseline Subjects willing discontinue use oral antibiotic therapy least 7 day prior baseline , unless prescribe acne treatment previously describe Subjects know allergy study product ingredient Women childbearing potential must willing use form birth control study . For purpose study , follow consider acceptable method birth control : oral contraceptive , Norplant , DepoProvera , double barrier method ( e.g. , condom spermicide ) abstinence . immunocompromised patient , subject extensive disease could reasonably controlled topical therapy history evidence condition would interfere evaluation study medication subject desire excessive prolonged exposure UV light ( e.g . sunlight/tanning bed ) study Use topical medication AD medical condition . Subjects currently involve another clinical research study . Subjects , pregnant , breast feeding planning pregnancy . Subjects clinically significant unstable medical mental disorder . Subjects unwilling unable comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>AD</keyword>
</DOC>